ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV Vaccine Candidate

ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV
Vaccine Candidate

ROCKVILLE, Md., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX)
a clinical-stage biopharmaceutical company creating novel recombinant
nanoparticle vaccines and vaccine adjuvants, today reported positive findings
from recent clinical and preclinical studies of its respiratory syncytial
virus F-protein (RSV F) nanoparticle vaccine candidate in poster sessions at
the 53^rd Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) in Denver, Colorado.

In a Phase 1 clinical study of 220 healthy elderly adults 60 years of age and
older (Poster B-501d: "RSV F Protein Vaccine Is Well-Tolerated and Immunogenic
in Elders"), Novavax' RSV F vaccine candidate was found to be compatible with
co-administration of an influenza vaccine, well-tolerated and elicited
increases in antibodies with potentially protective effects. In the study,
subjects were randomized to receive one dose of 60 or 90 micrograms of RSV F
protein with or without an aluminum adjuvant, or placebo. All subjects
received trivalent inactivated influenza vaccine to mimic anticipated
co-administration of both vaccines.The RSV F vaccine elicited up to a 5 fold
increase in serum anti-F IgGwith titers of palivizumab-competing antibodies
reaching 184µg/ml.Changes in all measures of RSV antibodies, including
microneutralization assays, were positively correlated.The RSV F vaccine did
not interfere with responses to the influenza vaccine.Top-line results from
this study were reported previously by Novavax in July.

In a separate preclinical study (Poster B-501a: "Passive Immunization with RSV
F Vaccine-Induced Polyclonal Antibodies Protect Cotton Rats From RSV A
Challenge"), investigators evaluated whether palivizumab-competing antibodies
induced by the RSV F vaccine could provide passive protection in a relevant
model. Palivizumab (Synagis®), a monoclonal antibody currently used to prevent
RSV disease, was previously studied in the cotton rat model, which provided
guidance for later licensing studies.

"These presentations reflect our progress in defining the importance of the
palivizumab-like antibody and confirm that the RSV F vaccine induces promising
immune responses in the elderly population," said Gregory Glenn, M.D., Senior
Vice President and Chief Medical Officer of Novavax. "These two studies are
important because they demonstrate the potential of our vaccine candidate to
prevent a major public health problem in the elderly and also provide
protection to infants through passive maternal immunization. These are
critical unmet needs which we plan to address in later-stage efficacy
studies."

Both posters are available under the "Publications and Presentations" section
of the Novavax website at www.novavax.com.

About RSV

RSV is a major respiratory pathogen in all humans regardless of age. In
healthy adults, RSV infections are generally mild to moderate in severity, but
may be more severe in infants and young children as well as the elderly and
adults with underlying chronic cardiac or pulmonary disease. It is estimated
that between 11-17,000 adults die of RSV infection annually in the U.S., with
up to 180,000 hospitalizations for serious respiratory symptoms. Globally, RSV
is a common cause of childhood respiratory infection, with a disease burden of
64 million cases and causing approximately 160,000 deaths annually. Severe RSV
disease results in 3.4 million hospital admissions per year globally and
disproportionately affects infants below six months of age. Currently, there
is no approved RSV prophylactic vaccine available.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using Innovative proprietary recombinant
protein nanoparticle vaccine technology, as well as new and efficient
manufacturing approaches, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Novavax is involved in several international partnerships, including
collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH, and recently acquired Isconova AB, a leading vaccine adjuvant
company located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about Novavax
is available on the company's website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and its ongoing
development of its recombinant nanoparticle vaccine products are
forward-looking statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed or implied by such
statements. These risks and uncertainties include those identified under the
heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2012, and Form 10-Q for the period ended June 30, 2013,
both filed with the Securities and Exchange Commission (SEC). Investors are
cautioned not to place considerable reliance on forward-looking statements
contained in this press release and encouraged to read the Company's filings
with the SEC, available at www.sec.gov, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this press release
speak only as of the date of this document, and Novavax undertakes no
obligation to update or revise any of the statements. Novavax' business is
subject to substantial risks and uncertainties, including those referenced
above and investors, potential investors, and others should give careful
consideration to these risks and uncertainties.

CONTACT: Barclay Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000

Novavax logo